{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:21:08Z","timestamp":1789608068171,"version":"build-2803163510"},"reference-count":98,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Frontline Gastroenterol"],"accepted":{"date-parts":[[2019,3,5]]},"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:p>Antibiotics and probiotics are often used as adjunctive therapy in inflammatory bowel disease. However, data are limited and randomised controlled trials are too inconsistent to provide generalised recommendations for their use in all patients with ulcerative colitis or Crohn\u2019s disease. Antibiotics are best used in the management of infectious complications and fistulas in Crohn\u2019s disease and, perhaps, in reducing the intensity of inflammation in luminal disease. Ciprofloxacin, metronidazole and rifaximin have been most widely used and studied. On the other hand, there appears to be a limited role for antibiotics in ulcerative colitis (UC). Probiotics are most effective in pouchitis, and may have a role in the initial therapy and maintenance of remission in mild UC; the probiotic cocktail VSL#3 has been the most widely studied. There is scant evidence of efficacy for probiotics in Crohn\u2019s disease.<\/jats:p>","DOI":"10.1136\/flgastro-2018-101057","type":"journal-article","created":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T17:15:34Z","timestamp":1553274934000},"page":"62-69","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":39,"title":["Antibiotics and probiotics in inflammatory bowel disease: when to use them?"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0308-1224","authenticated-orcid":false,"given":"Bincy","family":"Abraham","sequence":"first","affiliation":[{"name":"Gastroenterology and Hepatology, Houston Methodist, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eamonn M M","family":"Quigley","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology, Houston Methodist, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,3,22]]},"reference":[{"key":"2025090709350513000_11.1.62.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2015.09.008"},{"key":"2025090709350513000_11.1.62.2","doi-asserted-by":"crossref","first-page":"434","DOI":"10.4161\/gmic.20870","article-title":"Tip of the iceberg? The emergence of antibiotic-resistant organisms in the IBD population","volume":"3","author":"Nguyen","year":"2012","journal-title":"Gut Microbes"},{"key":"2025090709350513000_11.1.62.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2011.12.005"},{"key":"2025090709350513000_11.1.62.4","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-303184"},{"key":"2025090709350513000_11.1.62.5","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.72"},{"key":"2025090709350513000_11.1.62.6","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/ibd\/izy067","article-title":"Antibiotics in IBD: still a role in the biological era?","volume":"24","author":"Ledder","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2025090709350513000_11.1.62.7","doi-asserted-by":"publisher","DOI":"10.1159\/000081990"},{"key":"2025090709350513000_11.1.62.8","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq345"},{"key":"2025090709350513000_11.1.62.9","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.170225"},{"key":"2025090709350513000_11.1.62.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02879.x"},{"key":"2025090709350513000_11.1.62.11","unstructured":"Prantera C , Lochs H , Giochetti P , et al . Rifaximin-EIR (extended intestinal release) 400 mg tablets in the treatment of moderately active Crohn\u2019s disease: results of the international multicentre, randomised, double-blind, placebo-controlled trial RETIC-03. Gut 2010;59(Suppl 3)."},{"key":"2025090709350513000_11.1.62.12","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200201000-00002"},{"key":"2025090709350513000_11.1.62.13","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.34225"},{"key":"2025090709350513000_11.1.62.14","doi-asserted-by":"publisher","DOI":"10.1007\/BF02552649"},{"key":"2025090709350513000_11.1.62.15","first-page":"328","article-title":"An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin","volume":"91","author":"Prantera","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"2025090709350513000_11.1.62.16","doi-asserted-by":"publisher","DOI":"10.1136\/gut.32.9.1071"},{"key":"2025090709350513000_11.1.62.17","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0016-5085(82)80189-3","article-title":"A comparative study of metronidazole and sulfasalazine for active Crohn\u2018s disease: the cooperative Crohn\u2018s disease study in Sweden. II. Result","volume":"83","author":"Ursing","year":"1982","journal-title":"Gastroenterol"},{"key":"2025090709350513000_11.1.62.18","first-page":"513","article-title":"Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen","volume":"89","author":"Prantera","year":"1994","journal-title":"Am J Gastroenterol"},{"key":"2025090709350513000_11.1.62.19","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01099.x"},{"key":"2025090709350513000_11.1.62.20","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.031"},{"key":"2025090709350513000_11.1.62.21","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1542-3565(05)00020-0","article-title":"Antibiotic use and the risk of flare of inflammatory bowel disease","volume":"3","author":"Aberra","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025090709350513000_11.1.62.22","doi-asserted-by":"publisher","DOI":"10.1007\/BF01298873"},{"key":"2025090709350513000_11.1.62.23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.01842.x"},{"key":"2025090709350513000_11.1.62.24","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/0016-5085(80)90155-9","article-title":"Healing of perineal Crohn's disease with metronidazole","volume":"79","author":"Bernstein","year":"1980","journal-title":"Gastroenterology"},{"key":"2025090709350513000_11.1.62.25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0016-5085(82)80332-6","article-title":"Metronidazole therapy for perineal Crohn's disease: a follow-up study","volume":"83","author":"Brandt","year":"1982","journal-title":"Gastroenterology"},{"key":"2025090709350513000_11.1.62.26","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1155\/1993\/610272","article-title":"Combination of ciprofloxacin and metronidazole in severe perianal Crohn\u2019s disease","volume":"7","author":"Solomon","year":"1993","journal-title":"Can J Gastroenterol"},{"key":"2025090709350513000_11.1.62.27","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.7121"},{"key":"2025090709350513000_11.1.62.28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02247.x"},{"key":"2025090709350513000_11.1.62.29","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20608"},{"key":"2025090709350513000_11.1.62.30","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12216"},{"key":"2025090709350513000_11.1.62.31","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(95)90121-3"},{"key":"2025090709350513000_11.1.62.32","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.01.010"},{"key":"2025090709350513000_11.1.62.33","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1365-2036.2010.04231.x","article-title":"Meta-analysis: targeting the intestinal microbiota in prophylaxis for post-operative Crohn's disease","volume":"31","author":"Doherty","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"2025090709350513000_11.1.62.34","doi-asserted-by":"crossref","unstructured":"Campieri M , Rizzello F , Venturi A , et al . Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: a randomized controlled study vs mesalamine. Gastroenterology 2000;118.doi:10.1016\/S0016-5085(00)85267-1","DOI":"10.1016\/S0016-5085(00)85267-1"},{"key":"2025090709350513000_11.1.62.35","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000428910.36091.10"},{"key":"2025090709350513000_11.1.62.36","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/00004836-199207000-00007","article-title":"Rifabutin and ethambutol do not help recurrent Crohn's disease in the neoterminal ileum","volume":"15","author":"Rutgeerts","year":"1992","journal-title":"J Clin Gastroenterol"},{"key":"2025090709350513000_11.1.62.37","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-007-9760-1"},{"key":"2025090709350513000_11.1.62.38","first-page":"454","article-title":"A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis","volume":"92","author":"Mantzaris","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"2025090709350513000_11.1.62.39","doi-asserted-by":"publisher","DOI":"10.1080\/003655201750305503"},{"key":"2025090709350513000_11.1.62.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2014.06.001"},{"key":"2025090709350513000_11.1.62.41","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)70076-9"},{"key":"2025090709350513000_11.1.62.42","doi-asserted-by":"publisher","DOI":"10.1136\/gut.26.12.1380"},{"key":"2025090709350513000_11.1.62.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2014.05.010"},{"key":"2025090709350513000_11.1.62.44","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1365-2036.1990.tb00456.x","article-title":"The efficacy of tobramycin in the treatment of ulcerative colitis","volume":"4","author":"Burke","year":"1990","journal-title":"Aliment Pharmacol Ther"},{"key":"2025090709350513000_11.1.62.45","doi-asserted-by":"publisher","DOI":"10.1080\/00365520510023648"},{"key":"2025090709350513000_11.1.62.46","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.84"},{"key":"2025090709350513000_11.1.62.47","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026648812439"},{"key":"2025090709350513000_11.1.62.48","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2002.14.3.290"},{"key":"2025090709350513000_11.1.62.49","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-2036.1993.tb00084.x","article-title":"Oral tobramycin in ulcerative colitis: effect on maintenance of remission","volume":"7","author":"Lobo","year":"1993","journal-title":"Aliment Pharmacol Ther"},{"key":"2025090709350513000_11.1.62.50","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-199902000-00005"},{"key":"2025090709350513000_11.1.62.51","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200111000-00004"},{"key":"2025090709350513000_11.1.62.52","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00553.x"},{"key":"2025090709350513000_11.1.62.53","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01203.x"},{"key":"2025090709350513000_11.1.62.54","doi-asserted-by":"crossref","unstructured":"Shen B , Remzi FH , Lopez AR , et al . Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. BMC Gastroenterol 2008;8.doi:10.1186\/1471-230X-8-26","DOI":"10.1186\/1471-230X-8-26"},{"key":"2025090709350513000_11.1.62.55","doi-asserted-by":"publisher","DOI":"10.1007\/BF02093783"},{"key":"2025090709350513000_11.1.62.56","doi-asserted-by":"publisher","DOI":"10.3390\/nu5010058"},{"key":"2025090709350513000_11.1.62.57","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2014.66"},{"key":"2025090709350513000_11.1.62.58","unstructured":"Food and Agriculture Organization of the United Nations and World Health Organization . Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria, 2001. Available: http:\/\/www.who.int\/foodsafety\/publications\/fs_management\/en\/probiotics.pdf"},{"key":"2025090709350513000_11.1.62.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2017.08.003"},{"key":"2025090709350513000_11.1.62.60","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.03.024"},{"key":"2025090709350513000_11.1.62.61","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.3748\/wjg.v12.i21.3306","article-title":"Antibiotics and probiotics in treatment of inflammatory bowel disease","volume":"12","author":"Gionchetti","year":"2006","journal-title":"World J Gastroenterol"},{"key":"2025090709350513000_11.1.62.62","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2014.872627"},{"key":"2025090709350513000_11.1.62.63","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ085"},{"key":"2025090709350513000_11.1.62.64","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-200004000-00021"},{"key":"2025090709350513000_11.1.62.65","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2006.04535.x"},{"key":"2025090709350513000_11.1.62.66","doi-asserted-by":"crossref","unstructured":"Schultz M , Timmer A , Herfarth HH , et al . Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol 2004;4.doi:10.1186\/1471-230X-4-5","DOI":"10.1186\/1471-230X-4-5"},{"key":"2025090709350513000_11.1.62.67","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000175905.00212.2c"},{"key":"2025090709350513000_11.1.62.68","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.02.021"},{"key":"2025090709350513000_11.1.62.69","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.076604"},{"key":"2025090709350513000_11.1.62.70","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20063"},{"key":"2025090709350513000_11.1.62.71","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199712000-00021"},{"key":"2025090709350513000_11.1.62.72","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.10.031"},{"key":"2025090709350513000_11.1.62.73","doi-asserted-by":"crossref","unstructured":"Mallon P , McKay D , Kirk S , et al . Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2007;4.","DOI":"10.1002\/14651858.CD005573.pub2"},{"key":"2025090709350513000_11.1.62.74","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.218"},{"key":"2025090709350513000_11.1.62.75","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.07.016"},{"key":"2025090709350513000_11.1.62.76","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2008.118"},{"key":"2025090709350513000_11.1.62.77","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02268.x"},{"key":"2025090709350513000_11.1.62.78","doi-asserted-by":"crossref","unstructured":"Matthes H , Krummenerl T , Giensch M , et al . Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med 2010;10.doi:10.1186\/1472-6882-10-13","DOI":"10.1186\/1472-6882-10-13"},{"key":"2025090709350513000_11.1.62.79","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04939.x"},{"key":"2025090709350513000_11.1.62.80","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2010.08.006"},{"key":"2025090709350513000_11.1.62.81","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.00225.x"},{"key":"2025090709350513000_11.1.62.82","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)06343-0"},{"key":"2025090709350513000_11.1.62.83","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.037747"},{"key":"2025090709350513000_11.1.62.84","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02927.x"},{"key":"2025090709350513000_11.1.62.85","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20816"},{"key":"2025090709350513000_11.1.62.86","doi-asserted-by":"crossref","unstructured":"Guslandi M . Saccharomyces boulardii plus rifaximin in mesalamine-intolerant ulcerative colitis. J Clin Gastroenterol 2010;44.doi:10.1097\/MCG.0b013e3181cb4233","DOI":"10.1097\/MCG.0b013e3181cb4233"},{"key":"2025090709350513000_11.1.62.87","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/0016-5085(94)90832-X","article-title":"Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment","volume":"107","author":"Sandborn","year":"1994","journal-title":"Gastroenterology"},{"key":"2025090709350513000_11.1.62.88","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01465.x"},{"key":"2025090709350513000_11.1.62.89","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)00171-9"},{"key":"2025090709350513000_11.1.62.90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/208064","article-title":"Long-term use of probiotics Lactobacillus and Bifidobacterium has a prophylactic effect on the occurrence and severity of pouchitis: a randomized prospective study","volume":"2014","author":"Tomasz","year":"2014","journal-title":"Biomed Res Int"},{"key":"2025090709350513000_11.1.62.91","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s00595-015-1261-9","article-title":"The effect of Clostridium butyricum MIYAIRI on the prevention of pouchitis and alteration of the microbiota profile in patients with ulcerative colitis","volume":"46","author":"Yasueda","year":"2016","journal-title":"Surg Today"},{"key":"2025090709350513000_11.1.62.92","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2000.9370"},{"key":"2025090709350513000_11.1.62.93","doi-asserted-by":"publisher","DOI":"10.1136\/gut.53.1.108"},{"key":"2025090709350513000_11.1.62.94","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20369"},{"key":"2025090709350513000_11.1.62.95","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1111\/apt.12517","article-title":"Commentary: the effects of probiotics on barrier function and mucosal pouch microbiota during maintenance treatment for severe pouchitis in patients with ulcerative colitis","volume":"38","author":"Landy","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"2025090709350513000_11.1.62.96","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168785","article-title":"Methodological quality assessment of meta-analyses and systematic reviews of probiotics in inflammatory bowel disease and pouchitis","volume":"11","author":"Dong","year":"2016","journal-title":"PLoS One"},{"key":"2025090709350513000_11.1.62.97","doi-asserted-by":"crossref","unstructured":"Francino MP . Antibiotics and the human gut microbiome: dysbioses and accumulation of resistances. Front Microbiol 2015;6.doi:10.3389\/fmicb.2015.01543","DOI":"10.3389\/fmicb.2015.01543"},{"key":"2025090709350513000_11.1.62.98","doi-asserted-by":"publisher","DOI":"10.1038\/nature12820"}],"updated-by":[{"DOI":"10.1136\/flgastro-2018-101057corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000}}],"container-title":["Frontline Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/flgastro-2018-101057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T16:35:17Z","timestamp":1757262917000},"score":1,"resource":{"primary":{"URL":"https:\/\/fg.bmj.com\/lookup\/doi\/10.1136\/flgastro-2018-101057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,22]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12,6]]},"published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1136\/flgastro-2018-101057"],"URL":"https:\/\/doi.org\/10.1136\/flgastro-2018-101057","relation":{"correction":[{"id-type":"doi","id":"10.1136\/flgastro-2018-101057corr1","asserted-by":"object"}]},"ISSN":["2041-4137","2041-4145"],"issn-type":[{"value":"2041-4137","type":"print"},{"value":"2041-4145","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,22]]}}}